Back to all articles

Stopping Anti-TNF in Crohn’s Disease Remitters: Pros and Cons: The Pros.

“Stopping Anti-TNF in Crohn’s Disease Remitters: Pros and Cons: The Pros”, E. LOUIS (Department of Gastroenterology, University and CHU Liège, Liège, Belgium), Inflamm. Intest. Dis. 2022;7:64–68 (DOI: 10.1159/000520942).

For more information: BIOCYCLE website: biocycle-project.eu EU reference: grant agreement No 633168 – BIOCYCLE (PHC-13-2014).

10. Stopping Anti-TNF in CD PRO

Continue to read

Distinct biological profiles associated with the risk of short-term relapse and mid/long-term relapse in Crohn’s disease patients stopping infliximab.

10 janvier 2023

ECCO Topical Review on Biological Treatment Cycles in Crohn’s Disease.

A serum metabolite panel predicts Crohn’s disease relapse in patients discontinuing infliximab and continuing antimetabolite therapy: sub-analysis of the SPARE Trial.